

STUDY PROTOCOL

Open Access



Postponed or immediate drainage of infected necrotizing pancreatitis (POINTER trial): study protocol for a randomized controlled trial

Janneke van Grinsven^{1,2*} , Sven M. van Dijk^{1,2}, Marcel G. Dijkgraaf³, Marja A. Boermeester¹, Thomas L. Bollen⁴, Marco J. Bruno⁵, Sandra van Brunschot^{6,7}, Cornelis H. Dejong^{8,9}, Casper H. van Eijck¹⁰, Krijn P. van Lienden¹¹, Djamila Boerma², Peter van Duijvendijk¹², Muhammed Hadithi¹³, Jan Willem Haveman¹⁴, René W. van der Hulst¹⁵, Jeroen M. Jansen¹⁶, Daan J. Lips¹⁷, Eric R. Manusama¹⁸, I. Quintus Molenaar⁷, Donald L. van der Peet¹⁹, Alexander C. Poen²⁰, Rutger Quispel²¹, Alexander F. Schaapherder²², Erik J. Schoon²³, Matthijs P. Schwartz²⁴, Tom C. Seerden²⁵, B. W. Marcel Spanier²⁶, Jan Willem Straathof²⁷, Niels G. Venneman²⁸, Wim van de Vrie²⁹, Ben J. Witteman³⁰, Harry van Goor³¹, Paul Fockens⁶, Hjalmar C. van Santvoort^{2,7†}, Marc G. Besselink^{1*†} and for the Dutch Pancreatitis Study Group

Abstract

Background: Infected necrosis complicates 10% of all acute pancreatitis episodes and is associated with 15–20% mortality. The current standard treatment for infected necrotizing pancreatitis is the step-up approach (catheter drainage, followed, if necessary, by minimally invasive necrosectomy). Catheter drainage is preferably postponed until the stage of walled-off necrosis, which usually takes 4 weeks. This delay stems from the time when open necrosectomy was the standard. It is unclear whether such delay is needed for catheter drainage or whether earlier intervention could actually be beneficial in the current step-up approach. The POINTER trial investigates if immediate catheter drainage in patients with infected necrotizing pancreatitis is superior to the current practice of postponed intervention.

Methods: POINTER is a randomized controlled multicenter superiority trial. All patients with necrotizing pancreatitis are screened for eligibility. In total, 104 adult patients with (suspected) infected necrotizing pancreatitis will be randomized to immediate (within 24 h) catheter drainage or current standard care involving postponed catheter drainage. Necrosectomy, if necessary, is preferably postponed until the stage of walled-off necrosis, in both treatment arms. The primary outcome is the Comprehensive Complication Index (CCI), which covers all complications between randomization and 6-month follow up. Secondary outcomes include mortality, complications, number of (repeat) interventions, hospital and intensive care unit (ICU) lengths of stay, quality-adjusted life years (QALYs) and direct and indirect costs. Standard follow-up is at 3 and 6 months after randomization.

(Continued on next page)

* Correspondence: j.vangrinsven@pancreatitis.nl; m.g.besselink@amc.uva.nl

Hjalmar C van Santvoort and Marc G Besselink are shared senior author

†Hjalmar C. van Santvoort and Marc G. Besselink contributed equally to this work.

¹Department of Surgery, Amsterdam UMC, University of Amsterdam, G4.196, PO Box 26000, 1105 AZ Amsterdam, Netherlands

Full list of author information is available at the end of the article



(Continued from previous page)

Discussion: The POINTER trial investigates if immediate catheter drainage in infected necrotizing pancreatitis reduces the composite endpoint of complications, as compared with the current standard treatment strategy involving delay of intervention until the stage of walled-off necrosis.

Trial registration: ISRCTN, 33682933. Registered on 6 August 2015. Retrospectively registered.

Keywords: Necrotizing pancreatitis, Infection, Step-up approach, Timing, Drainage, Complication, Randomized controlled trial

Background

Acute pancreatitis is one of the most common gastrointestinal conditions requiring acute hospital admission [1]. Around 20–30% of these patients develop necrotizing pancreatitis [2]. Infected necrotizing pancreatitis occurs in a third of these patients and is associated with 15–20% mortality [3, 4], despite radiological, endoscopic or surgical interventions [3–6]. The current, 2013 international treatment guidelines [7, 8] recommend a step-up approach, based on the results of the Dutch PANTER trial [3]. The first step of this step-up approach is catheter drainage, preferably once the (extra) pancreatic collection has organized and has become fully encapsulated (walled-off necrosis). This process is usually complete 4 weeks after the onset of disease. During this time, intravenous antibiotic treatment is used which may obviate the need for any intervention in a small subset of patients [4]. If catheter drainage does not resolve the clinical signs of infection and sepsis, surgical [3] or endoscopic [9] necrosectomy is performed as the next step.

Postponing all interventions for infected necrosis until the stage of walled-off necrosis has been standard practice for many years. The rationale for this delay lies in the prevention of the “extra hit” (i.e. a pro-inflammatory reaction) of open surgery in these already critically ill patients, and in the relationship between early open necrosectomy and mortality [10]. In line with this practice, catheter drainage in the current step-up approach has also been postponed until the stage of walled-off necrosis. Meanwhile, intravenous antibiotics are administered to reduce systemic illness from the infected necrosis, which may lead to increased incidence of *Candida* infections and antibiotic resistance [10]. Notably, several observational studies have suggested that encapsulation is not mandatory for safe and successful catheter drainage [3, 11–15]. In other conditions, such as pancreatic fistula after pancreatic resection, early (percutaneous) catheter drainage has also proven to be safe and successful [16]. Furthermore, an international survey among expert pancreatologists demonstrated “equipose” between immediate and postponed catheter drainage of infected necrotizing pancreatitis [17]. The aim of immediate catheter drainage is to prevent further clinical deterioration.

Methods

The trial protocol is written in accordance with the Standard protocol items: recommendation for interventional trials (SPIRIT) guidelines (see Fig. 1 and the Additional file 1: SPIRIT checklist) [18].

Study aim

The POINTER trial aims to determine whether immediate catheter drainage in patients with (suspected) infected necrotizing pancreatitis is superior to the current standard of postponed catheter drainage with regard to clinical outcome and cost-effectiveness. The hypothesis is that pro-active diagnosis of infected necrosis and immediate catheter drainage prevents further clinical deterioration in these patients, reducing complications and possibly death, and reduces length of hospital stay and costs, as compared to postponing catheter drainage using antibiotics, preferably until the stage of walled-off necrosis.

Study design and setting

POINTER is a randomized controlled multicenter superiority trial, including hospitalized adult patients with proven or suspected infected necrotizing pancreatitis. In total, 25 centers are participating in the trial, including all 8 Dutch university medical centers. Endpoints are assessed by an adjudication committee, blinded to the assigned treatment arm, based on clinical case descriptions and endpoint definitions. The Data and Safety Monitoring Committee (DSMC) monitors patient safety.

Inclusion criteria (see Additional file 2: Table S1 and Additional file 3: Table S2)

The inclusion criteria are:

- Proven infected necrotizing pancreatitis (0–35 days after the onset of disease) or clinical suspected infected necrosis (15–35 days after the onset of disease)
- Catheter drainage of the necrotic collection is technically feasible, as deemed by the expert panel and/or treating physician (i.e. enough encapsulation and liquefaction)
- Age \geq 18 years

TIMEPOINT	STUDY PERIOD						
	Enrolment	Allocation	Primary study period			Follow-up	
	<i>Screening for infected necrosis</i>	<i>Diagnosing infected necrosis</i>	<i><24h After randomization</i>	<i>No clinical improvement</i>	<i>Walled-off necrosis</i>	<i>3 months</i>	<i>6 months</i>
	-t ₁	t ₀	t ₁	t ₂	t ₃	t ₄	t ₅
ENROLMENT	X						
Eligibility screen	X						
Informed consent	X						
Allocation		X					
INTERVENTIONS							
Direct drainage (A)			X				
Drain revision (A)*				X			
Necrosectomy (A)*					X		
Postponed drainage (B)*					X		
Drain revision (B)*					X		
Necrosectomy (B)*					X		
ASSESSMENTS							
Baseline variables ^β		X					
Primary outcome [^]							X
Secondary outcomes [#]						X	X

Fig. 1 SPIRIT schedule of enrollment, interventions, and assessments. *In the case of no clinical improvement. ^βBaseline variables: age, sex, center, body mass index, etiology of pancreatitis, American Society of Anesthesiologist’s classification, co-morbidity, disease severity, suspected or proven infected necrosis, time from admission to randomization, time from admission to tertiary referral. [^]Primary outcome: Comprehensive Complications Index. [#]Secondary outcomes: mortality, complications, number of (repeat) interventions, hospital and intensive care unit lengths of stay, quality-adjusted life years and direct and indirect costs

Exclusion criteria

The exclusion criteria are:

- Onset of acute pancreatitis > 35 days ago
- Indication for emergency laparotomy because of an abdominal catastrophe (e.g. bleeding, bowel perforation or abdominal compartment syndrome)
- Previous retroperitoneal intervention for necrotizing pancreatitis (ascites drainage is permitted and

(emergency) laparotomy without opening the bursa is permitted)

- Documented chronic pancreatitis (according to the M-ANNHEIM criteria [36], since this is a different disease entity)

Treatment groups

All patients with signs of infected necrotizing pancreatitis are pro-actively assessed for the presence of infected

necrosis, either by imaging (gas configurations), fine-needle aspiration (FNA), or clinical signs of infection, which may include persistent organ failure. See Additional file 4: Figure S1 for the inclusion flowchart. FNA is only used on indication and not as a screening tool. Patients who fulfill the eligibility criteria are randomly assigned to group A or B. Since diagnosing infected necrosis and making decisions on whether to perform invasive intervention in these patients are challenging, the Dutch pancreatitis expert panel [19] is 24 hours per day, 7 days per week, to assess indications for intervention and eligibility for randomization as was done in the PANTER [3] and TENSION [9] trials.

Intervention group (A)

Group A will receive immediate catheter drainage within 24 h after randomization, while starting (or continuing) antibiotic treatment. In the case of no clinical improvement within 72 h thereafter, the possibility of additional drainage is evaluated, including drain revision or drain upsizing. In the case of no clinical improvement thereafter, and no possibilities for additional catheter drainage, minimally invasive necrosectomy is performed once the (extra) pancreatic collection has developed into walled-off necrosis. No clinical improvement is defined as new organ failure or 2/3 parameters that do not decrease (temperature, C-reactive protein (CRP) and leukocyte count). See flowchart in Additional file 4: Figure S1.

Control group (B)

Group B will have postponed catheter drainage and receive antibiotics, preferably until the (extra) pancreatic necrotic collection has reached the stage of walled-off necrosis. In case of no clinical improvement within 72 h after drainage, the possibility of additional drainage is evaluated, including drain revision or drain upsizing. In case of no clinical improvement thereafter and no possibilities for additional catheter drainage, minimally invasive necrosectomy is performed. No clinical improvement is defined as new organ failure or 2/3 parameters that do not decrease (temperature, CRP and leukocyte count). See flowchart in Additional file 4: Figure S1.

Diagnosing infected necrosis

All patients with signs of infected necrotizing pancreatitis are screened for eligibility (Additional file 4: Figure S1). We differentiate between diagnosis of infected necrosis within the first 14 days after onset of disease and diagnosis thereafter. In the first 14 days a proven infection is mandatory, as in this early course of the disease it is impossible to distinguish systemic inflammatory response syndrome (SIRS) from sepsis. This proof requires either a positive gram stain or culture from FNA or gas configurations in the (peri) pancreatic collection with

necrosis, on imaging (contrast enhanced computed tomography (CECT) or magnetic resonance imaging (MRI)). In the case of unclear signs of infection, percutaneous FNA is performed in patients with necrotizing pancreatitis within 14 days after onset of disease who have had clinical signs of infection (i.e. new (multiple) organ failure or 2/3 parameters raised: temperature, CRP or leukocyte count) for 2 days consecutively. After the first 14 days, clinical signs of infection suffice for diagnosing infected necrosis (having no other focus for infection, e.g. pneumonia), based on our experiences in previous trials [3, 9]. Obviously, in the case of clinical doubt, FNA is still allowed after the first 14 days. The presence of gas in the (extra) pancreatic necrosis on CECT is considered proven infected necrosis in all patients, regardless of the disease stage (i.e. before or after 14 days).

Supportive treatment

Current standard management of acute (necrotizing) pancreatitis is extensively described in the International Association of Pancreatology (IAP)/American Pancreatic Association (APA) guidelines of 2013 [7]. These international guidelines have been adopted by the Dutch Pancreatitis Study Group (DPSG) and the national professional organizations involved. In accordance with these guidelines, patients receive fluid resuscitation, pain management and enteral feeding (or oral, if enteral feeding is not tolerated). Antibiotic prophylaxis is not given. The source of infection will be investigated in patients with clinical signs of infection and deterioration, by means of analysis of blood, urine, sputum, and ascites and by diagnostic imaging (e.g. chest x-ray and abdominal CECT). Once the focus of infection is identified, targeted antibiotics are given or, in when there infected necrosis is suspected and there is persistent deterioration, broad spectrum antibiotics with optimal tissue penetration are started empirically. The latter usually consists of meropenem or imipenem, based on the local antibiotics protocol.

Step-up approach

Both a percutaneous surgical and an endoscopic step-up approach are permitted in the POINTER trial, depending on the location of the necrotic collection(s), the extent of encapsulation and the preference of the treating physician. Transluminal (transgastric or transduodenal), endoscopic or percutaneous catheter drainage via the retroperitoneal route may be performed. In the case of no clinical improvement within the first 72 h after initial catheter drainage, an additional or upsizing drainage procedure is performed (Additional file 4: Figure S1). Necrosectomy is performed when there is no clinical improvement after this second drainage procedure and no further possibilities for optimized or additional drainage.

After percutaneous catheter drainage, additional necrosectomy should be performed surgically (e.g. videoscopic assisted retroperitoneal debridement (VARD)) and after endoscopic transluminal drainage, endoscopic transluminal necrosectomy is performed. Additional catheter drainage or necrosectomy may be performed using the “other” approach only when (additional) necrotic collections are not technically approachable using the standard second step. Both step-up approaches are performed to conform with the PANTER and TENSION trial protocols [3, 9]; see also Additional file 5: Figure S2 and Additional file 6: Figure S3. Randomized studies can be influenced by underestimation of learning curves, therefore in the POINTER trial the participating centers must have documented expertise, defined as having performed at least 10 independent VARD procedures, 10 independent endoscopic transluminal drainage procedures and 10 independent endoscopic transluminal necrosectomies. This number has been chosen to achieve a balance between volume and feasibility, and from experience with other trials of our study group including necrotizing pancreatitis patients [3, 9]. In the case of there being insufficient local experience available (e.g. during week-ends), the patient is transferred to a tertiary referral center with sufficient experience.

Primary endpoint

The primary endpoint is the Comprehensive Complications Index (CCI) [20, 21], including all complications other than pre-existent complications (e.g. treatment for infected (extra) pancreatic necrosis) occurring after randomization until 6 months after randomization, and graded according to the Clavien-Dindo classification. These complications are assessed by an adjudication committee, blinded for assigned treatment arm, based on clinical case descriptions using definitions.

Secondary endpoints

Secondary endpoints are mortality, new-onset (multiple) organ failure, bleeding requiring intervention, perforation of a visceral organ requiring intervention, enterocutaneous and pancreatic fistula, incisional hernia (including burst abdomen), wound infections, endocrine and exocrine pancreas insufficiency, number of patients with severe complications (Clavien-Dindo III or higher), number of patients per Clavien-Dindo classification, number of surgical, endoscopic and radiological (repeat) interventions, length of hospital stay, length of ICU admission, quality-adjusted life years (QALYs) and total direct and indirect costs (see Additional file 7 for relevant definitions). Also, for mutual comparison, the primary endpoint of the previous PANTER trial will be a secondary endpoint of the POINTER trial (i.e. a composite of major complications: new-onset multiple organ

failure, enterocutaneous fistula or perforation of a visceral organ requiring intervention, intra-abdominal bleeding requiring intervention or death during admission or during the 3 months after discharge) [3].

Sample size

The sample size was calculated based on the primary endpoint, the CCI. A mean CCI score of 40 (with standard deviation of 27) for postponed catheter drainage is based on the number of complications identified in the step-up arm of the PANTER trial [3] and TENSION trial [9]. Analysis by Student's *t* test will have 80% power to detect a clinically relevant reduction of 15 to a CCI score of 25 [21] at a significance level of 0.05; for a sample size that equals 2×51 , this will result in 102 evaluable patients. Assuming a dropout rate of about 2%, then 104 patients need to be included. A drop-out rate of 2% is relatively low, but was chosen from experience with other trials in our study group including patients with necrotizing pancreatitis, in which there was no loss to follow-up or drop-outs [3, 9].

Randomization, blinding and treatment allocation

Patients are randomized using a centrally operated computer (ALEA system) with variable block randomization for allocation concealment between group A (immediate catheter drainage) and group B (postponed catheter drainage). Stratification at randomization is applied for the following factors: presence of organ failure (yes versus no), disease duration (day 0–20 versus day 21–35) and center (expected high number of included patients versus other centers). For randomization of a patient, physicians can contact the study coordinator via telephone (www.pancreatitis.nl) 24 h per day, 7 days per week in order to check the eligibility criteria and to verify whether informed consent has been obtained. Blinding of patients and physicians to treatment strategy is not feasible, since both treatments are highly different timing-wise. Patients are coded by a numeric randomization code (anonymized).

Follow up

The follow-up duration is 6 months from randomization. Outpatient follow-up visits take place at the discretion of the responsible physician, but in any case, follow up at 3 and 6 months after randomization can be considered as standard care. All patients undergo imaging (preferably CECT) at 3 and 6 months post randomization. Furthermore, exocrine and endocrine pancreatic function is measured at these points in time, with blood glucose measurements and fecal elastase tests, respectively. No blood or fecal samples are stored at the DPSG data center. The treating physician is responsible for the application, interpretation and treatment when needed. Also, every patient receives a

combined questionnaire at home (Short Form-36 (SF-36) [22], Euroqol 5 dimensions (EQ-5D) [23], iMedical Consumption Questionnaire (iMCQ) [24] and iProductivity Cost Questionnaire (iPCQ) [25]) at 3 and 6 months. Data from patient records are collected until 6 months post randomization.

Baseline values

Baseline criteria (all < 24 h prior to randomization) are age, sex, center, body mass index, etiology of pancreatitis, American Society of Anesthesiologist's (ASA) classification, co-morbidity, disease severity (SIRS, ICU admission, single or multiple organ failure, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Multiple Organ Dysfunction Score (MODS) [26], Sequential Organ Failure Assessment (SOFA) score [27], CRP), CT severity index (CTSI), suspected or proven infected necrosis, time from admission to randomization (days) and time from admission to tertiary referral (days).

Statistical analysis

All randomized patients are evaluated for primary and secondary endpoints at 6 months after randomization. Using primary source data, an adjudication committee will assess the occurrence of the primary and secondary outcomes blinded to treatment allocation, after the last patient has completed the predefined follow up 6 months after randomization.

The primary analysis is based on intention-to-treat principles. For exploratory reasons per-protocol analysis will also be performed. A tabular listing of all patients excluded from the intention-to-treat populations will be provided together with the reasons for exclusion. For the intention-to-treat population the protocol deviations in each randomization arm are listed. Predefined subgroup analyses will be performed in patients with and without (multiple) organ failure and disease duration (cutoff 20 days) at the time of randomization and per center (high expected number of included patients and other centers).

All analyses will be performed in SPSS for Windows or SAS System for Windows. All data handling and analyses will be saved in a syntax/program file. Results will be presented with all centers combined. A two-tailed p value < 0.05 is considered statistically significant. No corrections for multiple tests will be applied.

The primary outcome is a sum of all complications that are weighted for their severity (multiplication of the median reference values from patients and physicians), the CCI [20, 21]. Comparison of the primary endpoint will be expressed in terms of the absolute difference in mean CCI score and standard deviation (SD). Subsequent analyses will be directed at the secondary endpoints. Data will be presented as mean \pm SD and in the case of skewed distributions as median and range. Values

will be compared using Student's t test, Wilcoxon's rank sum test, the chi square (χ^2) test or Fisher's exact test, as appropriate. In the event of imbalance between groups at baseline, regression analysis will be used to correct for the effect of the covariates.

The economic evaluation will address the question of whether or not immediate catheter drainage in patients with infected necrosis is cost-effective compared to the current management of postponed catheter drainage. A cost-effectiveness analysis and a cost-utility analysis will be performed, both from a societal perspective. The primary outcome parameters in the cost-effectiveness and cost-utility analyses, respectively, are the costs per unit of the CCI score and the costs per QALY.

Monitoring and quality assurance

Clinical trial monitoring is performed by an independent monitor. The trial monitor checks and verifies documents and reports in the trial patients' electronic or paper records at every site. The frequency may be changed based on the total enrollment period and enrollment rate. The monitor checks the site files according to the Medical Research Involving Human Subjects Act (WMO)/Good Clinical Practice (GCP) standards, as to whether and how essential documents are collected/administered and verifies all reported severe adverse events (SAEs). Also, the monitor verifies protocol compliance. A monitoring report is compiled after each monitoring visit at each specific site.

Safety

Physicians who are involved in the trial will be asked to report all adverse events to the coordinating investigator. The independent Data Safety Monitoring Committee (DSMC) will evaluate safety parameters at regular intervals. The DSMC consists of five members: two surgeons, a gastroenterologist, a radiologist and an epidemiologist. Evaluations are planned after patient number 25, 50 and 75 have completed their 6-month follow up. Deceased patients and every SAE that is possibly trial-related will be discussed unblinded by the DSMC, 25 patients at a time in 4 sessions. During the inclusion period of the study the DSMC performs interim analyses only on safety. Only for safety reasons as assessed by the DSMC will the POINTER trial be prematurely terminated. There will be no interim analysis of treatment effect. Adverse events are reported using the online module (<https://www.toetsinonline.nl>) of the Dutch Central Committee on Research involving human subjects.

Discussion

Infected necrosis is a potentially lethal complication of acute pancreatitis, typically requiring invasive intervention. The treatment of infected necrotizing pancreatitis is associated with lengthy hospital stay and high costs.

The POINTER trial is the first randomized controlled trial designed to determine the optimal timing of catheter drainage in infected necrotizing pancreatitis: i.e. immediate or postponed, once walled-off necrosis has occurred.

According to current evidence-based international guidelines [7, 8], suspected or proven infected necrosis in patients with clinical signs of infection is an indication for invasive intervention. There should be a strong reluctance towards intervening in sterile collections [7, 28]. Currently, intervention is advised when the infected necrosis has become walled-off, which occurs typically 4 weeks after the onset of disease [29]. This practice of postponing interventions until the stage of walled-off necrosis is based on literature published when open necrosectomy was the standard intervention [10, 30, 31]. Early necrosectomy is now recognized as having a major impact in the critically ill patient, whereas postponed necrosectomy allows the immune system to recover from the pro-inflammatory response due to pancreatitis.

Since the step-up approach is now considered standard of care, the issue of the optimal timing of catheter drainage has become highly relevant. Current literature reports that 35–64% of patients with infected necrotizing pancreatitis can be treated with catheter drainage alone, without the need for invasive necrosectomy [3, 5]. Therefore, several expert pancreatologists have stated that they already practice immediate catheter drainage in patients with infected necrosis. In a recent international survey performed in preparation for this study, 55% of expert pancreatologists stated that they typically postpone catheter drainage by using antibiotics, whereas the other 45% proclaimed to drain immediately after diagnosing infected necrosis [17]. Thus, in practice immediate catheter drainage is already being performed in individual patients, regardless of the effect of antibiotics alone or the degree of encapsulation: (percutaneous) catheter drainage in infected necrosis has been described retrospectively in several cohorts [32] at a median of 2 weeks (9–15 days) after the onset of disease instead of at 4 weeks (28 days).

Patient outcomes were significantly better in the step-up-approach arm of the PANTER trial compared to the control group (primary open necrosectomy), but mortality (19%) did not differ between the two groups [3]. The POINTER trial assesses whether early detection of infected necrosis and immediate catheter drainage improve outcomes, to further reduce mortality and morbidity. Earlier intervention may prevent patients from further deterioration while often waiting several weeks before undergoing invasive intervention, and thereby reduce complications and length of hospital stay and improve patient quality of life. In the control group, the effect of antibiotics is awaited while letting the (extra)

pancreatic necrotic collections become walled-off. Antibiotic treatment alone may suffice in a small minority of patients [4], which is another possible benefit for the control group.

Infected necrosis can be diagnosed on imaging (e.g. CECT) by the presence of gas in the (extra) pancreatic necrotic collection, irrespective of the source of the gas (i.e. through gas-forming bacteria or loss of integrity of the gastrointestinal tract). Collections with gas are seen in up to 42% of patients with infected necrosis [33] and can occur in every phase of the disease [34, 35]. Infected necrosis can also be confirmed by a positive gram stain or culture gathered with FNA. In a recent study, infected necrosis was confirmed by FNA in 86% (of 28 patients), which was similar to diagnosis based on clinical symptoms (80% of 92 patients) or gas identified on imaging (94% of 88 patients) [33]. Until recently, FNA was not routinely used in the Netherlands for diagnosing infected necrosis [17], as its outcome did not influence treatment because invasive intervention was postponed until the stage of walled-off necrosis, even in the case of a positive culture. In the POINTER trial, however, it is pivotal to detect infected necrosis as early as possible so as to perform immediate drainage (group A). Differentiating SIRS from sepsis is, however, very difficult in the first 14 days of the disease. Therefore, in the absence of gas on imaging but with clinical signs of infection in the first 14 days, a positive gram stain or culture after FNA is obligatory prior to randomization. Since the false negative rate of FNA is relatively high [33], a second FNA is advised in patients with persistent deterioration and a primary negative FNA. Clinical signs alone are sufficient to diagnose (suspected) infected necrotizing pancreatitis after the first 14 days [3].

After the first 14 days, clinical signs of infected necrosis are much more reliable. In the PANTER trial [3] it was possible to attain 91% accuracy in the identification of infected necrosis based on clinical criteria. Patients can be randomized in the POINTER trial after the first 14 days, based on the clinical diagnosis of infected necrosis, as was done in the PANTER trial [3].

Patients are randomized to undergo either immediate (< 24 h) or postponed (in walled-off necrosis) catheter drainage of infected collections. Both the surgical and the endoscopic step-up approach are allowed, depending on the location of the necrotic collection(s), the extent of encapsulation and the preference of the treating physician. It is known that both approaches are effective and safe and that not all (peri) pancreatic collections are approachable using a single technique [6, 9].

The CCI [20, 21] is the primary endpoint of the trial. Patients with infected necrotizing pancreatitis often have a long disease course with multiple complications, and therefore the CCI score is considered a representative

tool to take into account all these complications. The individual complications (e.g. organ failure and mortality), number of (repeat) interventions, hospital and ICU lengths of stay, QALYs and direct and indirect costs are also analyzed as secondary end points.

Patients are stratified based on organ failure at baseline, since it is known that patients with organ failure have poorer outcomes, as compared to patients with no organ failure. Patients are also stratified on disease duration (cut-off 20 days) since this is obviously related to the onset of walled-off necrosis. Finally, patients are stratified on expected high versus low volumes of patient inclusion.

In conclusion, the POINTER trial is a multicenter randomized controlled trial that investigates whether immediate catheter drainage reduces the CCI in patients with infected necrotizing pancreatitis, as compared to postponed catheter drainage.

Trial status

The trial was registered on 6 August 2015 as ISRCTN33682933 (<http://www.isrctn.com/ISRCTN33682933>). The first patient was randomized on 4 August 2015. To date, 88 of the 104 patients have been randomized and the inclusion of patients is on schedule.

Additional files

- Additional file 1:** SPIRIT checklist. (DOCX 46 kb)
- Additional file 2:** Table S1. Inclusion and exclusion criteria. (DOCX 14 kb)
- Additional file 3:** Table S2. Criteria for infected necrotizing pancreatitis. (DOCX 14 kb)
- Additional file 4:** Figure S1. Inclusion and randomization flowchart. (DOCX 33 kb)
- Additional file 5:** Figure S2. Surgical step-up approach [32, 37, 38]. (DOCX 253 kb)
- Additional file 6:** Figure S3. Endoscopic step-up approach [32, 37, 38]. (DOCX 169 kb)
- Additional file 7:** Relevant definitions. (DOCX 17 kb)

Abbreviations

APA: American Pancreatic Association; APACHE: Acute Physiology and Chronic Health Evaluation; ASA: American Society of Anesthesiologist's classification; CCI: Comprehensive Complication Index; CECT: Contrast enhanced computed tomography; CRP: C-reactive protein; CTSI: Computer Tomography Severity Index; DPGS: Dutch Pancreatitis Study Group; DSMC: Data Safety Monitoring Committee; FNA: Fine needle aspiration; GCP: Good Clinical Practice; IAP: International Association of Pancreatology; ICU: Intensive care unit; iMCQ: iMedical Consumption Questionnaire; iPCQ: iProductivity Cost Questionnaire; MODS: Multiple Organ Dysfunction Score; MRI: Magnetic resonance imaging; QALY: Quality-adjusted life year; SAE: Serious adverse event; SD: Standard deviation; SIRS: Systemic inflammatory response syndrome; SOFA: Sequential Organ Failure Assessment; SSI: Surgical site infection; VARD: Videoscopic assisted retroperitoneal debridement; WMO: Medical research involving human subjects act (in Dutch, *Wet Medisch-wetenschappelijk Onderzoek met mensen*)

Acknowledgements

Steering/adjudication committee

MG Besselink, MD PhD, dept. of surgery, Amsterdam UMC, University of Amsterdam (chair); HC van Santvoort, MD PhD, dept. of surgery, St. Antonius Hospital Nieuwegein and University Medical Center Utrecht; J van Grinsven, MD PhD, dept. of surgery, Amsterdam UMC, University of Amsterdam and St. Antonius Hospital Nieuwegein; SM van Dijk, MD, dept. of surgery, Amsterdam UMC, University of Amsterdam and St. Antonius Hospital Nieuwegein; MA Boermeester, MD PhD, dept. surgery, Amsterdam UMC, University of Amsterdam; TL Bollen, MD PhD, dept. of radiology, St. Antonius Hospital Nieuwegein; MJ Bruno, MD PhD, dept. of gastroenterology and hepatology, Erasmus MC University Medical Center Rotterdam; MG Dijkgraaf, PhD, clinical research unit, Amsterdam UMC, University of Amsterdam; KP van Lienden, MD PhD, dept. of radiology, Amsterdam UMC, University of Amsterdam; P Fockens, MD, PhD, dept. of gastroenterology and hepatology, Amsterdam UMC, University of Amsterdam. *Data safety monitoring committee*

JPH Drenth, MD PhD, dept. of gastroenterology and hepatology, Radboud University Medical Center Nijmegen (chair); DJ Gouma, MD PhD, dept. of surgery, Amsterdam UMC, University of Amsterdam; LPS Stassen, MD PhD, dept. of surgery, Maastricht University Medical Center; J Stoker, MD PhD, dept. of radiology, Amsterdam UMC, University of Amsterdam; S van Dieren, MD PhD, epidemiologist, Amsterdam UMC, University of Amsterdam.

Acute pancreatitis expert panel

MA Boermeester, MD PhD, dept. of surgery, Amsterdam UMC, University of Amsterdam; TL Bollen, MD PhD, dept. of radiology, St. Antonius Hospital Nieuwegein; MJ Bruno, MD PhD, dept. of gastroenterology and hepatology, Erasmus MC University Medical Center Rotterdam; VC Cappendijk, MD PhD, dept. of radiology, Jeroen Bosch Hospital 's-Hertogenbosch; CH Dejong, MD PhD, dept. of surgery, Maastricht University Medical Center; CH van Eijck, MD PhD, dept. of surgery, Erasmus MC University Medical Center Rotterdam; P Fockens, MD PhD, dept. of gastroenterology and hepatology, Amsterdam UMC, University of Amsterdam; H van Goor, MD PhD, dept. of surgery, Radboud University Medical Center Nijmegen; MG Besselink, MD PhD, dept. of surgery, Amsterdam UMC, University of Amsterdam; JW Haveman, MD PhD, dept. of surgery, University Medical Center Groningen, University of Groningen; HS Hofker, MD PhD, dept. of surgery, University Medical Center Groningen, University of Groningen; JS Laméris, MD PhD, dept. of radiology, Amsterdam UMC, University of Amsterdam; KP van Lienden, MD PhD, dept. of radiology, Amsterdam UMC, University of Amsterdam; VB Nieuwenhuijs, MD PhD, dept. of surgery, Isala Clinics Zwolle; JW Poley, MD PhD, dept. of gastroenterology and hepatology, Erasmus MC University Medical Center Rotterdam.

AF Schaapherder, MD PhD, dept. of surgery, Leids University Medical Center; R Timmer, MD PhD, dept. of gastroenterology and hepatology, St. Antonius Hospital Nieuwegein; HC van Santvoort, MD PhD, dept. of surgery, St. Antonius Hospital Nieuwegein and University Medical Center Utrecht.

Key staff at coordinating centers

MG Besselink, MD PhD, dept. of surgery, Amsterdam UMC, University of Amsterdam (principal investigator); HC van Santvoort, MD PhD, dept. of surgery, St. Antonius Hospital Nieuwegein and University Medical Center Utrecht (co-principal investigator); J van Grinsven, MD PhD, dept. of surgery, Amsterdam UMC, University of Amsterdam and St. Antonius Hospital Nieuwegein (study coordinator); SM van Dijk, MD, dept. of surgery, Amsterdam UMC, University of Amsterdam and St. Antonius Hospital Nieuwegein (study coordinator).

Clinical centers and principal investigators (all in the Netherlands)

1. Amsterdam UMC, University of Amsterdam, PO 22660, 1100 DD Amsterdam; MG Besselink, dept. of surgery.
2. Albert Schweitzer Hospital, PO 444, 3300 AK Dordrecht; W van de Vrie, dept. of gastroenterology and hepatology.
3. Amphia Hospital Breda, PO 90158, 4800 RK Breda; T Seerden, dept. of gastroenterology and hepatology.
4. Catharina Hospital, PO 1350, 5623 EJ Eindhoven; EJ Schoon, dept. of gastroenterology and hepatology.
5. Erasmus MC University Medical Center, PO 2040, 3000 CA Rotterdam; MJ Bruno, dept. of gastroenterology and hepatology.
6. Gelre Hospital, PO 9014, 7300 DS Apeldoorn; P van Duijvendijk, dept. of surgery.
7. Hospital Gelderse Vallei, PO 9025, 6710 HN Ede; BJ Witteman, dept. of gastroenterology and hepatology.
8. Isala Clinics, PO 10400, 8000 GK Zwolle; AC Poen, dept. of gastroenterology and hepatology.
9. Jeroen Bosch Hospital, PO 90153, 5200 ME 's-Hertogenbosch; DJ Lips, dept. of surgery.
10. Spaarne Gasthuis, PO 417, 2000 AK Haarlem; RW van der Hulst, dept. of gastroenterology and hepatology.

11. Leids University Medical Center, PO 9600, 2300 RC Leiden; AF Schaapherder, dept. of surgery.
12. Maastad Hospital Rotterdam, PO 9100, 3007 AC Rotterdam; M Hadithi, dept. of gastroenterology and hepatology.
13. Maastricht University Medical Center, PO 5800, 6202 AZ Maastricht; CH Dejong, dept. of surgery.
14. Maxima Medical Center, PO 7777, 5500 MB Veldhoven; JW Straathof, dept. of gastroenterology and hepatology.
15. Meander Medical Center, PO 1502, 3800 BM, Amersfoort; MP Schwartz, dept. of gastroenterology and hepatology.
16. Medical Center Leeuwarden, PO 888, 8901 BR Leeuwarden; ER Manusama, dept. of surgery.
17. Medisch Spectrum Twente, PO 50000, 7500 KA Enschede; NG Venneman, MD PhD, dept. of gastroenterology and hepatology.
18. OLVG Amsterdam, PO 95500, 1090 HM Amsterdam; JM Jansen, dept. of gastroenterology and hepatology.
19. Radboud University Nijmegen Medical Center, PO 9101, 6500 HB Nijmegen; H van Goor, dept. of surgery.
20. Reinier de Graaf Gasthuis, PO 5011, 2600 GA Delft; R Quispel, dept. of gastroenterology and hepatology.
21. Rijnstate Hospital, PO 9555, 6800 TA Arnhem; BMW Spanier, dept. of gastroenterology and hepatology.
22. St Antonius Hospital, PO 2500, 3430 EM Nieuwegein; D Boerma, dept. of surgery.
23. University Medical Center Groningen, PO 30001, 9700 RB Groningen; JW Haveman, dept. of surgery.
24. University Medical Center Utrecht, PO 85500, 3508 GA Utrecht; IQ Molenaar, dept. of surgery.
25. Amsterdam UMC, Vrije Universiteit van Amsterdam, PO 7057, 1007 MB Amsterdam; DL van der Peet, dept. of surgery.
Independent physician
PJ Tanis, MD PhD, dept. of surgery, Amsterdam UMC, University of Amsterdam.

Funding

The POINTER trial is an investigator-initiated trial. Financial support is provided by Fonds NutsOhra (grant number 1404-044), the Netherlands and the Amsterdam UMC, University of Amsterdam, the Netherlands. The Sponsors have no influence on the design of the study, data collection, results or publication.

Availability of data and materials

Patients are coded by a numeric randomization code (anonymized) and the principal investigators are the only ones to have access to this code. The source data are kept by the project leader for 15 years at the datacenter of the DPSG. All data generated or analyzed during this study will be included in the published results.

Authors' contributions

JvG drafted the manuscript. SMvD, HCvS and MGB co-authored the writing of the manuscript. JvG, HCvS, MAB, TLB, MJB, SvB, CHD, MGD, CHvE, KpVL, PF and MGB participated in the design of the study during several meetings of the Dutch Pancreatitis Study Group. JvG, MGB and MGD calculated the sample size. All authors critically assessed the study design, edited the manuscript and read and approved the final manuscript.

Ethics approval and consent to participate

The study is conducted according to the principles of the Declaration of Helsinki (59th version, October 2008) and in accordance with Dutch Law on research with humans (Medical Research Involving Human Subjects Act (WMO)). Central ethical approval has been confirmed from the medical research ethics committee of the Academic Medical Center Amsterdam on 19 June 2015 (METC 2015_033, NLS2361.018.15) and we will not begin recruiting at other centers in the trial until local ethical approval has been obtained. Important protocol modifications will be communicated to the central and local ethics committees. Patients are preferably recruited by the principal investigators. If this is not possible for practical reasons, he/she is replaced by a designated substitute (the study coordinator, local treating physicians or a study nurse) who is fully informed and aware of the study procedures and requirements. Written informed consent is obtained from each participant. In the case of incapacitated patients, informed consent is obtained from the patients' legal

representatives. This applies only to patients who are temporarily incapacitated because of the severity of pancreatitis.

Consent for publication

Not applicable, the study results will not contain any data from any individual person.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Surgery, Amsterdam UMC, University of Amsterdam, G4.196, PO Box 26000, 1105 AZ Amsterdam, Netherlands. ²Department of Surgery, St. Antonius Hospital Nieuwegein, Nieuwegein, Netherlands. ³Clinical Research Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. ⁴Department of Radiology, St. Antonius Hospital Nieuwegein, Nieuwegein, Netherlands. ⁵Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands. ⁶Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. ⁷Department of Surgery, University Medical Center Utrecht, Cancer Center, Utrecht, Netherlands. ⁸Department of Surgery, Maastricht University Medical Center+, Maastricht, Netherlands. ⁹NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands. ¹⁰Department of Surgery, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands. ¹¹Department of Radiology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. ¹²Department of Surgery, Gelre Hospital Apeldoorn, Apeldoorn, Netherlands. ¹³Department of Gastroenterology and Hepatology, Maastad Hospital Rotterdam, Rotterdam, Netherlands. ¹⁴Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. ¹⁵Department of Gastroenterology and Hepatology, Spaarne Gasthuis Haarlem, Haarlem, Netherlands. ¹⁶Department of Gastroenterology and Hepatology, OLVG Amsterdam, Amsterdam, Netherlands. ¹⁷Department of Surgery, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands. ¹⁸Department of Surgery, Medical Center Leeuwarden, Leeuwarden, Netherlands. ¹⁹Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands. ²⁰Department of Gastroenterology and Hepatology, Isala Clinics Zwolle, Zwolle, Netherlands. ²¹Department of Gastroenterology and Hepatology, Reinier de Graaf Gasthuis Delft, Delft, Netherlands. ²²Department of Surgery, Leids University Medical Center Leiden, Leiden, Netherlands. ²³Department of Gastroenterology and Hepatology, Catharina Hospital Eindhoven, Eindhoven, Netherlands. ²⁴Department of Gastroenterology and Hepatology, Meander Medical Center Amersfoort, Amersfoort, Netherlands. ²⁵Department of Gastroenterology and Hepatology, Amphia Hospital Breda, Breda, Netherlands. ²⁶Department of Gastroenterology and Hepatology, Rijnstate Hospital Arnhem, Arnhem, Netherlands. ²⁷Department of Gastroenterology and Hepatology, Maxima Medical Center Veldhoven, Veldhoven, Netherlands. ²⁸Department of Gastroenterology and Hepatology, Medisch Spectrum Twente Enschede, Enschede, Netherlands. ²⁹Department of Gastroenterology and Hepatology, Albert Schweitzer Hospital Dordrecht, Dordrecht, Netherlands. ³⁰Department of Gastroenterology and Hepatology, Hospital Gelderse Vallei Ede, Ede, Netherlands. ³¹Department of Surgery, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands.

Received: 13 November 2018 Accepted: 21 March 2019

Published online: 25 April 2019

References

1. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal diseases in the United States: 2012 update. *Gastroenterology*. 2012;143:1179–87.
2. Banks PA, Freeman ML. Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. *Am J Gastroenterol*. 2006;101:2379–400.

3. Van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. *N Engl J Med*. 2010;362:1491–502.
4. Van Santvoort HC, Bakker OJ, Bollen TL, Besselink MG, Ahmed Ali U, Schrijver AM, et al. A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. *Gastroenterology*. 2011;141:1254–63.
5. Van Baal MC, van Santvoort HC, Bollen TL, Bakker OJ, Besselink MG, Gooszen HG. Systematic review of percutaneous catheter drainage as primary treatment for necrotizing pancreatitis. *Br J Surg*. 2011;98:18–27.
6. Bakker OJ, van Santvoort HC, van Brunschot S, Geskus RB, Besselink MG, Bollen TL, et al. Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial. *JAMA*. 2012;307:1053–61.
7. Working group IAP/APA Acute pancreatitis guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatol*. 2013;13:e1–e15.
8. Tenner S, Baillie J, DeWitt J, Vege SS, American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. *Am J Gastroenterol*. 2013;108:1400–15 1416.
9. Van Brunschot S, van Grinsven J, Van Santvoort HC, Bakker OJ, Besselink MG, Boermeester MA, et al. Endoscopic or surgical step-up approach for infected necrotizing pancreatitis: a multicentre randomised trial. *Lancet*. 2018;391:51–8.
10. Besselink MG, Verwer TJ, Schoenmaeckers EJ, Buskens E, Ridwan BU, Visser MR, et al. Timing of surgical intervention in necrotizing pancreatitis. *Arch Surg*. 2007;142:1194–201.
11. Bruenler T, Langgartner J, Lang S, Wrede CE, Klebl F, Zierhut S, et al. Outcome of patients with acute, necrotizing pancreatitis requiring drainage - does drainage size matter? *World J Gastroenterol*. 2008;14:725–30.
12. Freeny PC, Hauptmann E, Althaus SJ, Traverso LW, Sinanan M. Percutaneous CT-guided catheter drainage of infected acute necrotizing pancreatitis: techniques and results. *AJR Am J Roentgenol*. 1998;170:969–75.
13. Lee JK, Kwak KK, Park JK, Yoon WJ, Lee SH, Ryu JK, et al. The efficacy of nonsurgical treatment of infected pancreatic necrosis. *Pancreas*. 2007;34:399–404.
14. Mortelé KJ, Girshman J, Szejnfeld D, Ashley SW, Erturk SM, Banks PA, et al. CT-guided percutaneous catheter drainage of acute necrotizing pancreatitis: clinical experience and observations in patients with sterile and infected necrosis. *AJR Am J Roentgenol*. 2009;192:110–6.
15. Zerem E, Imamović G, Sušić A, Haračić B. Step-up approach to infected necrotizing pancreatitis: a 20-year experience of percutaneous drainage in a single centre. *Dig Liver Dis*. 2011;43:478–83.
16. Poon RT, Fan ST, Lo CM, Ng KK, Yuen WK, Yeung C, et al. External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy a prospective randomized trial. *Ann Surg*. 2007;246:425–35.
17. Van Grinsven J, van Brunschot S, Bakker OJ, Bollen TL, Boermeester MA, Bruno MJ, et al. Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study. *HPB (Oxford)*. 2016;18:49–56.
18. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586.
19. Van Grinsven J, van Brunschot S, van Santvoort HC, Dutch Pancreatitis Study Group. The value of a 24/7 online nationwide multidisciplinary expert panel for acute necrotizing pancreatitis. *Gastroenterology*. 2017;152:685–8 e6.
20. Slankamenac K, Graf R, Barkun J, Puhon MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. *Ann Surg*. 2013;258:1–7.
21. Slankamenac K, Nederlof N, Pessaux P, de Jonge J, Wijnhoven BP, Breitenstein S, et al. The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in randomized controlled trials. *Ann Surg*. 2014;260:757–62.
22. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992;30:473–83.
23. Brooks R. EuroQol: the current state of play. *Health Policy*. 1996;37(1):53–72.
24. Bouwmans C, Hakkaart-van Roijen L, Koopmanschap M, Krol M, Severens H, Brouwer W. Handleiding iMTA Medical Consumption Questionnaire (iMCQ). Rotterdam: iMTA, Erasmus Universiteit; 2013.
25. Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Hakkaart-van Roijen L. The iMTA Productivity Cost Questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. *Value Health*. 2015;18:753–8.
26. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. *Crit Care Med*. 1995;23:1638–52.
27. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med*. 1996;22:707–10.
28. Rodriguez JR, Razo AO, Targarona J, Thayer SP, Rattner DW, Warshaw AL, et al. Debridement and closed packing for sterile or infected necrotizing pancreatitis: insights into indications and outcomes in 167 patients. *Ann Surg*. 2008;247:294–9.
29. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. *Gut*. 2013;62:102–11.
30. Fernández-del Castillo C, Rattner DW, Makary MA, Mostafavi A, McGrath D, Warshaw AL. Debridement and closed packing for treatment of necrotizing pancreatitis. *Ann Surg*. 1998;228:676–84.
31. Mier J, León EL, Castillo A, Robledo F, Blanco R. Early versus late necrosectomy in severe necrotizing pancreatitis. *Am J Surg*. 1997;173:71–5.
32. Van Grinsven J, van Santvoort HC, Boermeester MA, Dejong CH, van Eijck CH, Fockens P, et al. Timing of catheter drainage in infected necrotizing pancreatitis. *Nat Rev Gastroenterol Hepatol*. 2016;13:306–12.
33. Van Baal MC, Bollen TL, Bakker OJ, van Goor H, Boermeester MA, Dejong CH, et al. The role of routine fine-needle aspiration in the diagnosis of infected necrotizing pancreatitis. *Surgery*. 2014;155:442–8.
34. Besselink MG, van Santvoort HC, Boermeester MA, Nieuwenhuijs VB, van Goor H, Dejong CH, et al. Timing and impact of infections in acute pancreatitis. *Br J Surg*. 2009;96:267–73.
35. Van Grinsven J, van Brunschot S, van Baal MC, Besselink MG, Fockens P, van Goor H, et al. Natural history of gas configurations and encapsulation in necrotic collections during necrotizing pancreatitis. *J Gastrointest Surg*. 2018;22:1557–64.
36. Schneider A, Löhr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. *J Gastroenterol*. 2007;42:101–19.
37. Van Brunschot S, Bakker OJ, Besselink MG, Bollen TL, Fockens P, Gooszen HG, et al. Treatment of necrotizing pancreatitis. *Clin Gastroenterol Hepatol*. 2012;10:1190–201.
38. Da Costa DW, Boerma D, van Santvoort HC, Horvath KD, Werner J, Carter CR, et al. Staged multidisciplinary step-up management for necrotizing pancreatitis. *Br J Surg*. 2014;101:e65–79.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

